<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511520</url>
  </required_header>
  <id_info>
    <org_study_id>PTAF02-02/13</org_study_id>
    <nct_id>NCT04511520</nct_id>
  </id_info>
  <brief_title>Efficacy of Personalized Exercise Program and Trimetazidine in Rehabilitation of Patients After RFA of AF</brief_title>
  <official_title>Clinical Efficacy of Personalized Exercise Program and an Inhibitor of Fatty Acid β-oxidation in Rehabilitation of Patients With Atrial Fibrillation After Primary Radiofrequency Ablation of Pulmonary Venous Orifices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Preventive Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Medical Research Center for Therapy and Preventive Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is one of the most common forms of heart rhythm disorder in patients&#xD;
      with cardiovascular diseases. The choice of treatment for AF is a complex problem, depending&#xD;
      on the form (paroxysmal, persistent, permanent) of AF, clinical manifestations of cardiac&#xD;
      arrhythmias, associated diseases, the effectiveness of antiarrhythmic drugs. The accumulated&#xD;
      data to date indicate an efficacy of the method of radiofrequency ablation (RFA) in the&#xD;
      treatment of the paroxysmal form of AF. The RFA procedure does not eliminate the pathological&#xD;
      processes that take place during developed AF. This dictates the need to develop and test new&#xD;
      technologies and physical rehabilitation programmes for patients. The positive clinical&#xD;
      effects of physical rehabilitation programmes based on moderate-intensity exercises are well&#xD;
      known. The search for drugs capable of improving the results of RFA for AF in patients&#xD;
      becomes urgent. This creates the prerequisites for the study of the clinical efficacy of&#xD;
      trimetazidine MV in the rehabilitation of patients with cardiac diseases who underwent&#xD;
      treatment of AF with RFA, which will optimize the management of such patients in the&#xD;
      inpatient and outpatient setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is interventional (Clinical Trial), randomized in parallel groups. Enrollment: 72&#xD;
      participants.&#xD;
&#xD;
      The 72 male patients were randomized in 3 groups. In 1st group (control) patients were taken&#xD;
      antiarrhythmical drugs and anticoagulants. They did only usual activity without walking.&#xD;
      Patients in 2nd group were taken antiarrhythmical drugs and anticoagulants, participated in&#xD;
      rehabilitation programme. Twice a week they came in clinical center to engage in physical&#xD;
      training with an instructor. The programe was lasted for 6 months. Also patients did they&#xD;
      usual physical activity, practiced walking. Patients in 3rd group were taken antiarrhythmical&#xD;
      drugs and anticoagulants, selective inhibitor of fat acids oxidation for 6 months. They did&#xD;
      only usual activity without walking.&#xD;
&#xD;
      The examination was carried for all 72 patients. Before RFA patients took blood tests,&#xD;
      performed echocardiography, completed psychological questionnaires. After 3 days they took&#xD;
      blood tests, performed 6-minute walk testing, ECG monitoring, completed psychological&#xD;
      questionnaires. One month after RFA patient performed veloergometry testing. Three months&#xD;
      after RFA the performed 6-minute walk testing, ECG monitoring, took blood tests, completed&#xD;
      psychological questionnaires. Six months after RFA patients took blood tests, performed&#xD;
      echocardiography, 6-minute walk testing, ECG monitoring, veloergometry testing, completed&#xD;
      psychological questionnaires. Onward was a follow up period for 6 months. At the time point&#xD;
      of 12 months patients took blood tests, performed echocardiography, ECG monitoring,&#xD;
      veloergometry testing, completed psychological questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial Fibrillation Recurrence</measure>
    <time_frame>From RFA to 3 months</time_frame>
    <description>Number of participants with reccurrence of atrial fibrillation after RFA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial Fibrillation Recurrence</measure>
    <time_frame>From 3 months to 6 months</time_frame>
    <description>Number of participants with recurrence of atrial fibrillation after RFA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial Fibrillation Recurrence</measure>
    <time_frame>From 6 months to 12 months</time_frame>
    <description>Number of participants with recurrence of atrial fibrillation after RFA</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Atrial Fibrillation Paroxysmal</condition>
  <arm_group>
    <arm_group_label>Physical training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trimetazidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of trimetazidine in addition to standart therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard follow-up at the participating heart center</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical training program</intervention_name>
    <arm_group_label>Physical training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine</intervention_name>
    <arm_group_label>Trimetazidine</arm_group_label>
    <other_name>fatty acids beta-oxidation inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  treated for atrial fibrillation with radiofrequency ablation&#xD;
&#xD;
          -  cardiac disease&#xD;
&#xD;
          -  providing written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital and acquired heart defects.&#xD;
&#xD;
          -  Acute coronary syndrome (unstable angina, myocardial infarction), myocardial&#xD;
             revascularization during the previous 6 months&#xD;
&#xD;
          -  Transient ischemic attack, stroke in history.&#xD;
&#xD;
          -  Arterial hypertension (BP ≥160/100 мм. рт. ст.)&#xD;
&#xD;
          -  The risk of thromboembolic complications on a scale CHA2DS2-VASc&gt; 2&#xD;
&#xD;
          -  Risk of hemorrhagic complications of anticoagulant therapy (HAS-BLED&gt; 3 points on the&#xD;
             scale).&#xD;
&#xD;
          -  Complications after RFA.&#xD;
&#xD;
          -  Chronic heart failure above III FC (NYHA), ejection fraction (EF) &lt;40%.&#xD;
&#xD;
          -  Acute thrombophlebitis, complicated forms of varicose veins (thrombophlebitis,&#xD;
             phlebothrombosis).&#xD;
&#xD;
          -  Pronounced atherosclerosis of peripheral arteries (intermittent claudication),&#xD;
             requiring surgical intervention.&#xD;
&#xD;
          -  Violation of conductivity: AV-blockade 2-3 degrees, complete blockade of the bundle of&#xD;
             the His bundle&#xD;
&#xD;
          -  The presence of an implanted pacemaker pacemaker / pacemaker with a resynchronization&#xD;
             function/cardioverter-defibrillator)&#xD;
&#xD;
          -  Conduct RFA on AF earlier.&#xD;
&#xD;
          -  The presence of a history of syncopal states.&#xD;
&#xD;
          -  Diabetes mellitus type 1 and 2 in the stage of decompensation.&#xD;
&#xD;
          -  Acute conditions: infection, exacerbation of chronic diseases in a period of less than&#xD;
             1 month prior to the study; severe injury, surgical interventions other than RFA for a&#xD;
             period of less than 2 months from the start of the study&#xD;
&#xD;
          -  Renal failure (creatinine levels above 300 µmol / L or 3.5 mg / dL).&#xD;
&#xD;
          -  Patient's refusal to participate in the study&#xD;
&#xD;
          -  Alcohol and drug abuse.&#xD;
&#xD;
          -  Peptic ulcer and duodenal ulcer in history.&#xD;
&#xD;
          -  Obesity, body mass index (BMI) ≥40 kg / m2&#xD;
&#xD;
          -  Intake of Trimetazidine MB and its analogues for 3 months. before inclusion in&#xD;
             research.&#xD;
&#xD;
          -  The presence of any disease that, according to the doctor, prevents the inclusion of&#xD;
             the patient in the study.&#xD;
&#xD;
          -  unable to understand study instructions&#xD;
&#xD;
          -  with considerable illness in the musculoskeletal system or with physical disability,&#xD;
             which complicates exercise training&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <results_first_submitted>April 28, 2021</results_first_submitted>
  <results_first_submitted_qc>April 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2021</results_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rehabilitation</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>physical training</keyword>
  <keyword>radiofrequency ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimetazidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>study protocol</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>until December 2020</ipd_time_frame>
    <ipd_access_criteria>study protocol will be available upon request</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were no significant study events</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Physical Training</title>
          <description>Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)&#xD;
Physical training program</description>
        </group>
        <group group_id="P2">
          <title>Trimetazidine</title>
          <description>Treatment of trimetazidine in addition to standard therapy&#xD;
Trimetazidine</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>Standard follow-up at the participating heart center</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Physical Training</title>
          <description>Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)&#xD;
Physical training program</description>
        </group>
        <group group_id="B2">
          <title>Trimetazidine</title>
          <description>Treatment of trimetazidine in addition to standart therapy&#xD;
Trimetazidine</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>Standard follow-up at the participating heart center</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="8.5"/>
                    <measurement group_id="B2" value="56.4" spread="8.1"/>
                    <measurement group_id="B3" value="55.0" spread="9.8"/>
                    <measurement group_id="B4" value="56.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Atrial Fibrillation Recurrence</title>
        <description>Number of participants with reccurrence of atrial fibrillation after RFA</description>
        <time_frame>From RFA to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Physical Training</title>
            <description>Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)&#xD;
Physical training program</description>
          </group>
          <group group_id="O2">
            <title>Trimetazidine</title>
            <description>Treatment of trimetazidine in addition to standard therapy&#xD;
Trimetazidine</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Standard follow-up at the participating heart center</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Fibrillation Recurrence</title>
          <description>Number of participants with reccurrence of atrial fibrillation after RFA</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Atrial Fibrillation Recurrence</title>
        <description>Number of participants with recurrence of atrial fibrillation after RFA</description>
        <time_frame>From 3 months to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Physical Training</title>
            <description>Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)&#xD;
Physical training programme</description>
          </group>
          <group group_id="O2">
            <title>Trimetazidine</title>
            <description>Treatment of trimetazidine in addition to standard therapy&#xD;
Trimetazidine</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Standard follow-up at the participating heart center</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Fibrillation Recurrence</title>
          <description>Number of participants with recurrence of atrial fibrillation after RFA</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Atrial Fibrillation Recurrence</title>
        <description>Number of participants with recurrence of atrial fibrillation after RFA</description>
        <time_frame>From 6 months to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Physical Training</title>
            <description>Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)&#xD;
Physical training program</description>
          </group>
          <group group_id="O2">
            <title>Trimetazidine</title>
            <description>Treatment of trimetazidine in addition to standard therapy&#xD;
Trimetazidine</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Standard follow-up at the participating heart center</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Fibrillation Recurrence</title>
          <description>Number of participants with recurrence of atrial fibrillation after RFA</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Physical Training</title>
          <description>Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)&#xD;
Physical training program</description>
        </group>
        <group group_id="E2">
          <title>Trimetazidine</title>
          <description>Treatment of trimetazidine in addition to standart therapy&#xD;
Trimetazidine</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>Standard follow-up at the participating heart center</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Maria Makhinova</name_or_title>
      <organization>National medical research center for therapy and preventive medicine</organization>
      <phone>+79104803524</phone>
      <email>longtimeaftertomorrow@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

